News and Press Releases

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 30, 2024

675 West Kendall St Cambridge, MA 02142 USA

DRUG DISCOVERY 2024: CONNECTING MINDS, TRANSFORMING SCIENCE, EMPOWERING COMMUNITY

We are proud to be media partners of ELRIG's Drug Discovery 2024! Europe’s largest conference for the drug discovery community returns to London, with scientific tracks covering not only therapeutic...

Category: Drug Discovery
Posted: August 29, 2024

ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK

Introducing Endotoxin Testing with PYROSTAR™ Neo+

A wildlife-conscious recombinant alternative to the conventional LAL assay 28 August 2024 -- Eastleigh, England -- In line with its sustainability ethics, Alpha Laboratories is delighted to introduce the new...

Category: Biotechnology, Other, Pharmaceutical
Posted: August 28, 2024

Alpha Laboratories Ltd., 40 Parham Drive, Eastleigh, SO50 4NU, Hampshire, UK

Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III

26 August, 2024 – New Jersey, US – Merck, known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in...

Category: Pharmaceutical
Posted: August 28, 2024

1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

European Commission Approves Astellas’ PADCEVTM (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years European Marketing Authorization based on positive overall survival and...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 28, 2024

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan

CPHI Korea 2024 opens with 15% growth as innovation booms in Korea

Event’s most international edition sees health ingredients, nutraceuticals and biopharma driving growth 27 August 2024 – Korea – CPHI Korea – at the heart of Korea’s pharmaceutical industry – opens...

Category: Pharmaceutical
Posted: August 28, 2024

Hall C COEX, Seoul

PCI Pharma Services’ Bedford, New Hampshire Location Successfully Completes International Coalition of Medicines Regulatory Authorities Inspection

PCI is the first CDMO to undergo ICMRA’s inspection pilot program. 21 August 2024 - Philadelphia, US – PCI Pharma Services (PCI), a leading global contract development and manufacturing organization...

Category: Manufacturing and Packing
Posted: August 27, 2024

3001 Red Lion Road, Philadelphia, PA 19114, USA

Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis

23 August 2024  –Lund, Sweden – Hansa Biopharma AB, (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US President has decided to...

Category:
Posted: August 27, 2024

Scheelevägen 22 Lund, Sweden, 223 63

European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy

Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 27, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Stockholm3 independently validated at the world-renowned Martini Klinik

23 August 2024 – Stockholm, Sweden – Stockholm3 has been independently, externally validated at the Martini Klinik, the world-renowned prostate cancer center in Hamburg, Germany. The Martini validation study demonstrated...

Category: Clinical Trials
Posted: August 27, 2024

Kungsgatan 24, SE 111 35 Stockholm, Sweden

European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma

First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR3 alterations Approval based on THOR results,...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 23, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2

Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval 22 August 2024 -- Massachusetts, US -- Moderna, Inc today...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 22, 2024

Global Headquarters 200 Technology Square Cambridge, MA 02139

Data Supporting FDA Approval Published in High-Impact Journal

Publication of results from ANGLE’s Parsortix PC1 system validates use of Parsortix System for CTC isolation and harvest in metastatic breast cancer 22 August 2024 -- Guilford, UK -- ANGLE...

Category: Biotechnology, Other, Pharmaceutical
Posted: August 22, 2024

2 Occam Court, Occam Road, Surrey Research Park, Guilford, GU2 7QB

Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project  

Small Molecules Identified for Therapeutic Intervention in Oncology and Inflammation Edinburgh, Scotland, and Villigen, Switzerland, 20 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in...

Category: Drug Discovery
Posted: August 22, 2024

Belfast The Innovation Centre Queens Rd, Belfast, BT3 9DT

SGS Introduces New Specialized Bioanalytical Testing Services in North America

21 August 2024 -- Geneva, Switzerland -- SGS, the world’s leading testing, inspection and certification company, announces the introduction of new specialized bioanalytical testing services in the North American pharmaceutical...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: August 21, 2024

1 Place des Alpes P.O. Box 2152 1211 Geneva 1 Switzerland